Literature DB >> 7923320

Valuation of medical resource units collected in health economic studies.

C Copley-Merriman1, T J Lair.   

Abstract

This paper reviews the issues that are critical for the valuation of medical resources in the context of health economic studies. There are several points to consider when undertaking the valuation of medical resources. The perspective of the analysis should be established before determining the valuation process. Future costs should be discounted to present values, and time and effort spent in assigning a monetary value to a medical resource should be proportional to its importance in the analysis. Prices vary considerably based on location of the service and the severity of the illness episode. Because of the wide variability in pricing data, sensitivity analysis is an important component of validation of study results. A variety of data sources have been applied to the valuation of medical resources. Several types of data are reviewed in this paper, including claims data, national survey data, administrative data, and marketing research data. Valuation of medical resources collected in clinical trials is complex because of the lack of standardization of the data sources. A national pricing data source for health economic valuation would greatly facilitate study analysis and make comparisons between results more meaningful.

Mesh:

Year:  1994        PMID: 7923320

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.

Authors:  J Mauskopf; K Schulman; L Bell; H Glick
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

2.  Pharmacoeconomic analysis of stress ulcer prophylaxis for critically ill patients.

Authors:  G T Schumock; N P Lam; S R Winkler; S X Kong
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 3.  A critical review of published economic modelling studies in depression.

Authors:  M T Jones; P C Cockrum
Journal:  Pharmacoeconomics       Date:  2000-06       Impact factor: 4.981

4.  The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios.

Authors:  Elinor C G Chumney; Andrea K Biddle; Kit N Simpson; Morris Weinberger; Kathryn M Magruder; William N Zelman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.